Cara Therapeutics Inc (CARA) concluded trading on Wednesday at a closing price of $0.26, with 22.95 million shares of worth about $5.97 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 6.29% during that period and on December 18, 2024 the price saw a gain of about 4.97%. Currently the company’s common shares owned by public are about 54.85M shares, out of which, 45.77M shares are available for trading.
Stock saw a price change of -1.84% in past 5 days and over the past one month there was a price change of -10.39%. Year-to-date (YTD), CARA shares are showing a performance of -64.72% which decreased to -58.34% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.24 but also hit the highest price of $1.17 during that period. The average intraday trading volume for Cara Therapeutics Inc shares is 552.86K. The stock is currently trading -6.55% below its 20-day simple moving average (SMA20), while that difference is down -8.07% for SMA50 and it goes to -44.04% lower than SMA200.
Cara Therapeutics Inc (NASDAQ: CARA) currently have 54.85M outstanding shares and institutions hold larger chunk of about 24.70% of that.
The stock has a current market capitalization of $14.38M and its 3Y-monthly beta is at 0.68. It has posted earnings per share of -$1.75 in the same period. It has Quick Ratio of 4.71 while making debt-to-equity ratio of 61.97. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CARA, volatility over the week remained 11.40% while standing at 9.09% over the month.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Stifel on June 13, 2024 offering a Hold rating for the stock and assigned a target price range of between $6 and $1 to it. On June 13, 2024, H.C. Wainwright Downgrade their recommendations, while on June 13, 2024, Canaccord Genuity Downgrade their ratings for the stock with a price target of $1. Stock get an Underperform rating from BofA Securities on March 08, 2023.
